Zacks Research Analysts Lower Earnings Estimates for MMSI

Merit Medical Systems, Inc. (NASDAQ:MMSI) – Stock analysts at Zacks Research decreased their Q3 2026 earnings estimates for Merit Medical Systems in a research report issued to clients and investors on Thursday, May 21st. Zacks Research analyst Team now anticipates that the medical instruments supplier will post earnings per share of $0.90 for the quarter, down from their previous estimate of $0.91. The consensus estimate for Merit Medical Systems’ current full-year earnings is $3.61 per share. Zacks Research also issued estimates for Merit Medical Systems’ Q1 2027 earnings at $0.84 EPS, Q2 2027 earnings at $0.96 EPS, Q4 2027 earnings at $1.04 EPS and FY2027 earnings at $3.83 EPS.

Merit Medical Systems (NASDAQ:MMSI) last released its quarterly earnings results on Thursday, April 30th. The medical instruments supplier reported $0.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.84 by $0.10. The firm had revenue of $381.88 million during the quarter, compared to the consensus estimate of $377.59 million. Merit Medical Systems had a net margin of 9.03% and a return on equity of 13.54%. The company’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.86 earnings per share. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS.

Several other equities analysts also recently issued reports on the stock. Wells Fargo & Company dropped their price target on shares of Merit Medical Systems from $78.00 to $74.00 and set an “equal weight” rating for the company in a research note on Friday, May 1st. Canaccord Genuity Group dropped their price target on shares of Merit Medical Systems from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Wall Street Zen cut shares of Merit Medical Systems from a “strong-buy” rating to a “buy” rating in a research report on Sunday, April 5th. Weiss Ratings cut shares of Merit Medical Systems from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, May 8th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Merit Medical Systems from $95.00 to $77.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Eight investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $92.80.

Merit Medical Systems Price Performance

MMSI stock opened at $64.17 on Monday. The company has a fifty day moving average price of $66.86 and a 200-day moving average price of $77.72. The company has a market capitalization of $3.83 billion, a P/E ratio of 27.78, a PEG ratio of 2.00 and a beta of 0.58. Merit Medical Systems has a 52-week low of $59.74 and a 52-week high of $97.18. The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.46 and a current ratio of 5.08.

Institutional Investors Weigh In On Merit Medical Systems

Large investors have recently bought and sold shares of the stock. Los Angeles Capital Management LLC acquired a new stake in Merit Medical Systems in the fourth quarter worth $25,000. Maseco LLP acquired a new stake in Merit Medical Systems in the fourth quarter worth $26,000. Torren Management LLC acquired a new stake in Merit Medical Systems in the fourth quarter worth $38,000. Covestor Ltd grew its holdings in Merit Medical Systems by 252.6% in the fourth quarter. Covestor Ltd now owns 469 shares of the medical instruments supplier’s stock worth $41,000 after purchasing an additional 336 shares during the period. Finally, Danske Bank A S acquired a new stake in Merit Medical Systems in the third quarter worth $42,000. 99.66% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Merit Medical Systems

In related news, insider Brian G. Lloyd purchased 2,000 shares of Merit Medical Systems stock in a transaction on Thursday, May 7th. The stock was acquired at an average cost of $62.62 per share, for a total transaction of $125,240.00. Following the completion of the acquisition, the insider owned 2,000 shares of the company’s stock, valued at $125,240. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Lynne N. Ward sold 5,000 shares of the firm’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $62.61, for a total transaction of $313,050.00. Following the completion of the sale, the director owned 7,809 shares of the company’s stock, valued at $488,921.49. The trade was a 39.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 0.70% of the company’s stock.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.